Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
All-cause mortality rates were highest among those with NAFLD-related cirrhosis.
However, people with cirrhosis alone were as likely to die as those with both cirrhosis and COVID-19.
A recent Swedish study defined a low-level detectable viral load as between 50 and 999.
Some experts have doubted the link between sustained virologic response and clinical outcomes.
Liver scarring was associated with poorer health outcomes and a higher risk of death for people with non-alcoholic fatty liver disease.
Curing hep C slashes risk of death for those with liver cancer history
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
A new classification system may more accurately reflect liver-related death trends in the United States.
This held true regardless of the type of hep C treatment—interferon-based or direct-acting antiviral.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
Researchers call for greater use of noninvasive measures of fatty liver disease in this population to identify those at risk.
Researchers analyzed autopsies among people with HIV who died in New York City since 1984.
Researchers have presented findings from the first large cohort of people followed over a lengthy period to assess this connection.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
A new study appears to resolve controversy over hep C treatment’s association with mortality risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.